Research
Hormonal
Obesity results from a failure of the central hypothalamic satiety mechanism (specifically the ventromedial nucleus) to inhibit the lateral feeding center, leading to hyperphagia, rather than from a simple failure of peripheral stomach sensations.
Focus on the quality and metabolic impact of food (specifically glucose utilization) rather than just volume or stomach sensations. The brain regulates intake based on how nutrients are processed, not just physical distension.
GoodSupportsHIGH confidence
Although some cases of obesity are attributable directly to failure of the central regulatory mechanism, others may be the single end result of neurological, endocrine, enzymatic, and psychological conditions which have very little in common.
Why this rating
Based on extensive animal lesion studies (rats, mice, cats, monkeys) and human physiological correlations, though not a modern clinical trial.
Source
Regulation of Food Intake and Obesity
Jean Mayer et al. · Science · 1967
DOI 10.1126/science.156.3773.328
narrative_reviewCited 313×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The ventromedial nucleus of the hypothalamus acts as a 'satiety center' that inhibits the lateral 'feeding center'; destruction of this area causes hyperphagia and obesity due to a failure to terminate feeding, not an increase in the motivation to start eating.Good
- Short-term food intake regulation is driven by a 'glucostatic' mechanism where glucose utilization in the ventromedial hypothalamus triggers satiety, rather than blood glucose concentration alone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →